Literature DB >> 17268061

Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells.

Dan Li1, Li-Jun Wu, Shin-ichi Tashiro, Satoshi Onodera, Takashi Ikejima.   

Abstract

Oridonin, an active component isolated from the plant Rabdosia rubescens, has been reported to exhibit antitumor effects, but little is known about its molecular mechanism of action. In this study, we first investigated the mechanism involved in oridonin-induced cell death in human epidermoid carcinoma A431 cells, which overexpress epidermal growth factor receptor (EGFR). After treatment with various doses of oridonin for 24 h, the majority of A431 cells underwent apoptosis in a time- and dose-dependent manner as measured by an LDH activity-based assay. Treatment with oridonin at various concentrations for 24 h caused significant inhibition on the total tyrosine kinase activities and downregulation of EGFR expression or EGFR phosphorylation. Oridonin significantly affected the localization of EGFR and phosphorylated EGFR on the cell membrane. However, genistein (a well-known tyrosine kinase inhibitor) did not induce apoptotic A431 cell death. Importantly, oridonin exhibited much stronger inhibitory effect on the total tyrosine kinase activities or EGFR tyrosine phosphorylation as well as much stronger suppression on EGFR and phosphorylated EGFR localization than genistein in A431 cells. Taken together, oridonin exerted a potential inhibitory effect on the tyrosine kinase activity of A431 cells. The decrease in the tyrosine kinase activity and the blockage of EGFR tyrosine phosphorylation might be one of the causes of oridonin-induced A431 cell death.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17268061     DOI: 10.1248/bpb.30.254

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  8 in total

1.  Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.

Authors:  Yong Guo; Qingqing Shan; Yuping Gong; Juan Lin; Xi Yang; Ruiqing Zhou
Journal:  Cancer Biol Ther       Date:  2012-08-16       Impact factor: 4.742

2.  Epidermal regeneration by ent-16α, 17-dihydroxy-kauran-19-oic acid isolated from Siegesbeckia pubescens.

Authors:  S-H Sung; S-H Park; S-Y Song; S-J Lee; H-W Lee; S-H Kim; M A Lee; I-S Yoon; D-D Kim; S Kang; J-H Sung
Journal:  Cell Prolif       Date:  2011-10-13       Impact factor: 6.831

Review 3.  Oridonin: targeting programmed cell death pathways as an anti-tumour agent.

Authors:  Z Liu; L Ouyang; H Peng; W-Z Zhang
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

4.  Anti-cancer natural products isolated from chinese medicinal herbs.

Authors:  Wen Tan; Jinjian Lu; Mingqing Huang; Yingbo Li; Meiwan Chen; Guosheng Wu; Jian Gong; Zhangfeng Zhong; Zengtao Xu; Yuanye Dang; Jiajie Guo; Xiuping Chen; Yitao Wang
Journal:  Chin Med       Date:  2011-07-22       Impact factor: 5.455

5.  Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response.

Authors:  Yu Du; Nicole F Villeneuve; Xiao-Jun Wang; Zheng Sun; Weimin Chen; Jixue Li; Hongxiang Lou; Pak Kin Wong; Donna D Zhang
Journal:  Environ Health Perspect       Date:  2008-09       Impact factor: 9.031

Review 6.  Molecular Insight in the Multifunctional Effects of Oridonin.

Authors:  Brice Ayissi Owona; Herman J Schluesener
Journal:  Drugs R D       Date:  2015-09

Review 7.  Natural products: a hope for glioblastoma patients.

Authors:  Raghupathy Vengoji; Muzafar A Macha; Surinder K Batra; Nicole A Shonka
Journal:  Oncotarget       Date:  2018-04-24

8.  Simultaneous characterization and quantification of 17 main compounds in Rabdosia rubescens by high performance liquid chromatography.

Authors:  Sen Guo; Xueqin Cui; Mi Jiang; Lu Bai; Xiao Tian; Tiantian Guo; Qingchao Liu; Li Zhang; Chi-Tang Ho; Naisheng Bai
Journal:  J Food Drug Anal       Date:  2016-07-26       Impact factor: 6.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.